bluebird bio Inc (BLUE) Insider Sells $242,100.00 in Stock

bluebird bio Inc (NASDAQ:BLUE) insider David Davidson sold 2,000 shares of the firm’s stock in a transaction on Tuesday, December 4th. The shares were sold at an average price of $121.05, for a total value of $242,100.00. Following the completion of the sale, the insider now owns 30,905 shares in the company, valued at $3,741,050.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

David Davidson also recently made the following trade(s):

  • On Friday, November 2nd, David Davidson sold 5,000 shares of bluebird bio stock. The shares were sold at an average price of $133.64, for a total value of $668,200.00.
  • On Tuesday, October 2nd, David Davidson sold 5,000 shares of bluebird bio stock. The shares were sold at an average price of $139.32, for a total value of $696,600.00.

Shares of BLUE traded down $4.80 during midday trading on Thursday, reaching $108.85. 1,220,407 shares of the stock were exchanged, compared to its average volume of 687,376. bluebird bio Inc has a twelve month low of $102.21 and a twelve month high of $236.17. The stock has a market capitalization of $6.22 billion, a P/E ratio of -14.12 and a beta of 2.37.



bluebird bio (NASDAQ:BLUE) last posted its earnings results on Thursday, November 1st. The biotechnology company reported ($2.73) EPS for the quarter, topping the Zacks’ consensus estimate of ($2.90) by $0.17. bluebird bio had a negative return on equity of 31.50% and a negative net margin of 1,326.02%. The business had revenue of $11.50 million for the quarter, compared to analysts’ expectations of $6.90 million. During the same quarter in the previous year, the firm earned ($1.73) earnings per share. The business’s revenue was up 49.2% compared to the same quarter last year. As a group, equities research analysts forecast that bluebird bio Inc will post -10.71 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently bought and sold shares of BLUE. Capital International Investors increased its position in shares of bluebird bio by 188.6% during the third quarter. Capital International Investors now owns 3,260,636 shares of the biotechnology company’s stock worth $476,053,000 after purchasing an additional 2,130,927 shares in the last quarter. Capital World Investors increased its position in shares of bluebird bio by 37.4% during the third quarter. Capital World Investors now owns 3,425,687 shares of the biotechnology company’s stock worth $500,150,000 after purchasing an additional 931,932 shares in the last quarter. FMR LLC increased its position in shares of bluebird bio by 8.1% during the third quarter. FMR LLC now owns 8,123,687 shares of the biotechnology company’s stock worth $1,186,058,000 after purchasing an additional 605,797 shares in the last quarter. Capital Research Global Investors increased its position in shares of bluebird bio by 8.1% during the third quarter. Capital Research Global Investors now owns 6,634,317 shares of the biotechnology company’s stock worth $968,610,000 after purchasing an additional 494,787 shares in the last quarter. Finally, Vanguard Group Inc. increased its position in shares of bluebird bio by 10.1% during the third quarter. Vanguard Group Inc. now owns 4,619,413 shares of the biotechnology company’s stock worth $674,435,000 after purchasing an additional 422,866 shares in the last quarter.

A number of research firms have weighed in on BLUE. Piper Jaffray Companies cut bluebird bio from an “overweight” rating to a “neutral” rating and cut their price target for the company from $240.00 to $120.00 in a research note on Thursday. ValuEngine cut bluebird bio from a “strong-buy” rating to a “buy” rating in a research note on Monday, September 17th. BidaskClub cut bluebird bio from a “hold” rating to a “sell” rating in a research note on Tuesday, September 11th. Cantor Fitzgerald set a $122.00 price target on bluebird bio and gave the company a “sell” rating in a research note on Thursday, August 23rd. Finally, Maxim Group restated a “hold” rating on shares of bluebird bio in a research note on Monday. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and seventeen have assigned a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $194.80.

COPYRIGHT VIOLATION WARNING: “bluebird bio Inc (BLUE) Insider Sells $242,100.00 in Stock” was originally posted by Dakota Financial News and is owned by of Dakota Financial News. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The legal version of this news story can be viewed at https://dakotafinancialnews.com/2018/12/06/bluebird-bio-inc-blue-insider-sells-242100-00-in-stock.html.

About bluebird bio

bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent ß-thalassemia and severe sickle cell disease.

Featured Article: Conference Calls

Insider Buying and Selling by Quarter for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply